A 25-year follow-up of a population screened with faecal occult blood test in Finland

Acta Oncologica

Volumn 46, Issue 8, 2007, Pages 1103-1106

  Malila, Nea ^a   Hakama, Matti ^a   Pukkala, Eero ^a  

^a FINNISH CANCER REGISTRY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PATIENT COMPLIANCE; PRIORITY JOURNAL;

COHORT STUDIES; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; OCCULT BLOOD; PATIENT COMPLIANCE; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 35848965057     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701442531     Document Type: Article

References (14)

1. Moller B, Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talbäck M, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev 2002;11(Suppl 1):S1-S96.
2. Finnish Cancer Registry. Cancer in Finland 2002 and 2003. Helsinki: Cancer Society of Finland; 2005.
3. Adlercreutz H, Liewendahl K, Virkola P. Evaluation of Fecatest, a new guaiac test for occult blood in feces. Clin Chem 1978;24:756-61.
4. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002;41:381-8.
5. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348(9040):1467-71.
7. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994;29:468-73.
8. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
9. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348(9040):1472-7.
10. Steele RJ, Parker R, Patnick J, Warner J, Fraser C, Mowat NA, et al. A demonstration pilot trial for colorectal cancer screening in the United Kingdom: A new concept in the introduction of healthcare strategies. J Med Screen 2001;8:197-202.
11. Weller D, Alexander FE, Orbell S, Campbell H, Szczepura A, Forbes J, et al. Evaluation of the UK Colorectal Cancer Screening Pilot. Edinburgh: University of Edinburgh; 2003.
12. Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: Details of the national screening programme implemented in Autumn. J Med Screen ;12 2004;2005:28-32.
13. Cervix Cancer Screening, Vol. 10. IARC Handbooks of cancer prevention. Lyon: IARC Press; 2005.
14. Mandel JS, Bond JH, Bradley M, Snover DC, Church TR, Williams S, et al. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology 1989;97:597-600.